权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Single-molecule counting of circular RNAs using phage nanoparticles as surrogates

使用噬菌体纳米颗粒作为替代物对环状 RNA 进行单分子计数

基本信息

批准号：
10092159
负责人：
Binrui Cao
金额：
$ 22.79万
依托单位：
UNIVERSITY OF OKLAHOMA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-02-01 至 2022-05-06
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10092159
关键词：
Affinity Bacteria Bacteriophage T7 Bacteriophages Binding Biological Assay Biological Markers Biomedical Engineering Biosensing Techniques Body Fluids Breast Cancer Cell Breast Cancer Patient Buffers Capsid Cells Chemicals Clinic Code Color Complementary DNA Complex Detection Engineering Eye Fiber Genetic Genetic Engineering Goals Hour Human In Vitro Letters Magnetism Mammary Neoplasms Mammography Methods Modification Nanotechnology Nucleic Acids Oligonucleotides Peptides Phosphate Buffer Polymerase Chain Reaction Proteins RNA Reproducibility Resolution Reverse Transcription Saline Sampling Sensitivity and Specificity Series Serum Sodium Chloride Specificity Structure Tail Techniques Testing Time Tissues Tumor Tissue Untranslated RNA Virus Virus-like particle Visual Water Woman aptamer aqueous base breast cancer diagnosis cancer biomarkers cancer diagnosis cancer therapy circular RNA cost design detection limit digital early detection biomarkers malignant breast neoplasm millimeter nanobiomaterial nanomaterials nanoparticle novel overexpression particle protein biomarkers red fluorescent protein single molecule

项目摘要

Single-molecule counting of circular RNAs using phage nanoparticles as surrogates Abstract Circular RNA (circRNA) have been considered as promising breast cancer biomarkers, but the current qRT-PCR and digital PCR techniques for quantifying them have some inherent limitations. T7 phage, a human-safe virus nanoparticle specifically infecting bacteria, can be plated to infect bacteria in a plaque-forming assay to form millimeter-scale plaques in a one to one format and at a single-particle resolution within 3 hours. Inspired from this, we propose to develop a phage plaque counting (PPC) strategy that hires bioengineered fluorescent T7 phage as a surrogate to establish a one-to-one correspondence among target circRNA, phage nanoparticles, and eye-visible phage-developed plaques, enabling us to simultaneously quantify multiple circRNA biomarkers in a single test by simply counting the corresponding plaques. Briefly, a fluorescent phage probe with an oligonucleotide (ONT-1) capable of capturing one unique segment of a target circRNA, and a magnetic microparticle (MMP) probe with an ONT-2 capable of capturing another unique segment of the same target, co- capture the target to form a sandwich complex where phages and target molecules are equimolar. Then the phages are released and plated to develop fluorescent plaques in a one to one format, thus counting the plaques at the single-particle level leads to visualized quantification of the target circRNA at a single-molecule level. A fluorescent protein on the capsid makes the corresponding plaque fluoresce a unique color and enables the simultaneous single-particle quantification of fluorescent plaques (in the same Petri dish) with each color coding one target (i.e., by displaying green and red fluorescent protein for two corresponding targets). We hypothesize that our PPC strategy with optimized conditions can simultaneously quantify a panel of two circRNAs as breast cancer biomarkers in human serum with high sensitivity, specificity, and reproducibility. Aim 1: Establish and optimize PPC strategy for quantifying single and multiple circRNA breast cancer biomarkers. We will produce and purify the target circRNAs (circ_0001785 and circ_100219) by the overexpression method and use the PPC method to quantify them with a series of dilutions in water. We will optimize the PPC and identify its detection limit. Aim 2: Validate the PPC strategy for simultaneously quantifying multiple circRNA biomarkers in breast cancer cells, tissues, and human serum. We will first use MMPs that can capture the target circRNAs to magnetically remove the pre-existing target circRNAs from the commercial human serum, which is then used to make serum samples with known concentrations of target circRNAs. Then we will employ and optimize the PPC to quantify the target circRNAs in the serum. We will also isolate total RNAs from breast cancer cells and in vitro breast tumor tissues to form aqueous RNA solutions by a commercial RNA isolation kit. We will then use the PPC to quantify the target circRNAs in the resultant RNA solutions and the commercial total RNA solutions isolated from tumor tissues of breast cancer patients. This project will lead to a new visualized single-molecule technique for quantifying circRNA biomarkers for breast cancer diagnosis.

以噬菌体纳米颗粒为替代物的环状rna单分子计数